End-of-day quote
Shenzhen S.E.
03:30:00 07/05/2024 am IST
5-day change
1st Jan Change
22.38
CNY
+0.99%
+2.29%
+1.82%
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022
May 13, 2023 at 01:02 am IST
Amoy Diagnostics Co., Ltd. at its Annual General Meeting held on 11 May 2023 approved final cash dividend of CNY 1.40000000 per 10 shares (tax included) for 2022.
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
22/04
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
15/04
CI
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.
01/04
CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index
11/12
CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index
11/12
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23/23/23
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
31/23/31
CI
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China
26/23/26
MT
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023
17/23/17
CI
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022
13/23/13
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
21/23/21
CI
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022
18/23/18
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
14/23/14
CI
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC
27/23/27
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
14/23/14
CI
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million.
13/23/13
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
03/23/03
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
24/22/24
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
10/22/10
CI
Alercell® to Distribute Amoydx® Ros1 Gene Fusion Detection Kit
08/22/08
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
29/22/29
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
04/22/04
CI
Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022
26/22/26
CI
Amoy Diagnostics Co., Ltd. Approves Dividend for 2021
13/22/13
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
20/22/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Companyâs testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
More about the company
Last Close Price
22.38
CNY
Average target price
28.6
CNY
Spread / Average Target
+27.78%
Consensus
1st Jan change
Capi.
+1.82% 1.21B -0.80% 12.65B -1.68% 8.01B +0.69% 5.35B +22.60% 5.23B +1.03% 4.69B -53.29% 3.26B +13.22% 2.64B -7.55% 2.23B -0.46% 1.94B
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1